These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26553313)

  • 1. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
    Choe YM; Kim KW; Jhoo JH; Ryu SH; Seo EH; Sohn BK; Byun MS; Bak JH; Lee JM; Yun HJ; Han MI; Woo JI; Lee DY
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):731-9. PubMed ID: 26553313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.
    An H; Choi B; Park KW; Kim DH; Yang DW; Hong CH; Kim SY; Han SH
    J Alzheimers Dis; 2017; 55(2):727-735. PubMed ID: 27716660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Lepola UM; Loft H; Reines EH
    Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial.
    Vander Wal JS; Gang CH; Griffing GT; Gadde KM
    J Clin Psychopharmacol; 2012 Jun; 32(3):341-5. PubMed ID: 22544016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
    Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
    J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of selective serotonin reuptake inhibitors-related antidepressants in Alzheimer's disease: a meta-analysis.
    Wang H; Li S; Zhang J; Peng W; Li T; Zhang J
    Eur J Med Res; 2024 Aug; 29(1):438. PubMed ID: 39210432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.
    Mayer LS; Bay RC; Politis A; Steinberg M; Steele C; Baker AS; Rabins PV; Lyketsos CG
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):930-6. PubMed ID: 16955427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
    Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
    Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
    Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
    Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
    Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
    Stahl SM; Gergel I; Li D
    J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
    Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
    JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.